Fortis Healthcare Distances Itself From Daiichi-Singh Brothers Dispute Amid SC Audit

Fortis Healthcare has stated it is not involved in the ongoing legal dispute between Daiichi Sankyo and the Singh Brothers. This comes after the Supreme Court allowed a forensic audit into the matter, reaffirming that Fortis faces no penalties or liabilities from the High Court's judgment.

Fortis Healthcare has stated it is not involved in the ongoing legal dispute between Daiichi Sankyo and the Singh Brothers. This comes after the Supreme Court allowed a forensic audit into the matter, reaffirming that Fortis faces no penalties or liabilities from the High Court's judgment.

Fortis Healthcare, a prominent Indian healthcare provider, has clarified its position regarding the long-running legal dispute between Japanese pharmaceutical firm Daiichi Sankyo and the Singh Brothers, formerly associated with RHC Holding. The company firmly stated that it considers itself a 'complete stranger' to the arbitration dispute.

This clarification from Fortis Healthcare follows a significant development in the case: the Supreme Court has permitted a forensic audit into the contentious matter. The apex court affirmed that its previous observations regarding the dispute were tentative, paving the way for a detailed examination of the facts.

No Penalties for Fortis

Fortis Healthcare has emphatically underlined that no penalties or liabilities were imposed on the company in the High Court's judgment concerning this specific dispute. This statement aims to reassure stakeholders that, despite the ongoing legal battle involving its former promoters, the company itself is not directly implicated financially or legally.

The dispute primarily revolves around an arbitration award granted in favour of Daiichi Sankyo against the Singh Brothers. Fortis Healthcare has consistently sought to distance itself from this legal entanglement, asserting its independent operational and financial standing.

Singh Brothers' Diminished Stake

Further supporting its claim of non-involvement, Fortis Healthcare highlighted the significant reduction in the Singh Brothers' shareholding in the company. By March 2018, the collective shareholding of the Singh Brothers in Fortis Healthcare had dropped to below 1%. This substantial reduction in ownership effectively diminished their direct control and influence over the healthcare provider, thereby strengthening Fortis's argument that it should not be held responsible for the personal legal disputes of its former promoters.

The Supreme Court's decision to allow a forensic audit signals a deeper investigation into the financial intricacies and responsibilities related to the Daiichi-Singh Brothers dispute. While the broader implications for the parties directly involved remain significant, Fortis Healthcare's clear stance aims to insulate the company from potential repercussions of a case in which it claims no direct involvement.

This report is for informational purposes only and should not be considered as investment advice.